Quantum precision reached in modeling molten salt behavior
Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
In the mid-1980s, Balendra Sutharshan moved to Canada from the island nation of Sri Lanka. That move set Sutharshan on a path that had him heading continent-spanning collaborations and holding leadership posts at multiple Department of Energy
For years Brenda Smith found fulfillment working with nuclear batteries, a topic she’s been researching as a chemist at Oak Ridge National Laboratory.
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.